In this work, the authors calibrated the VPop by estimating relative prevalence of tumor growth phenotypes from their QSP model describing the link between EGFR activation, MAPK signaling pathway and tumor growth using clinical data from three Ph1b studies with combinations of EGFR, BRAF and MEK inhibitors. This evidence concerns the gene BRAF and neoplasm.